Midatech Pharma Share Discussion Threads

[valuetracker] 05/2/2021 07:30

Go watch it. I'm sure it will be online somewhere. All factual.

[best1467] 05/2/2021 07:29

Ramptastic

[valuetracker] 05/2/2021 07:12

Anyone remember the webcast in late 2020? The one where they spoke of multiple BILLION pound deals in the pipeline? Q1 2021 wasn't it?

RNS this afternoon as per the norm?

[wapper] 05/2/2021 07:09

Up 40% in USA overnight

[w1lbur01] 04/2/2021 15:41

Ready for lift off loves a Friday rise!

[wapper] 04/2/2021 13:13

Zak Mir just covered MTPH on Sharetalk's lunchtime Bulletin Board Heroes .Says above 34p mid price should see 70p by end March. Stop loss : a fall below 28p which is the 50 day moving average

[wapper] 04/2/2021 09:33

Off topic but VAL looking very good for a decent run. Been tracking for weeks and it's just started in last 5 minutes DYOR of course

[georgethefourth] 04/2/2021 09:08

They updated the website which probably got a bit of attention. The thing I like about this is how quiet it is on the boards. The Twitter feed is practically dead and no one seems to be in. A bit of good news and this will move fast

[aberloon2] 04/2/2021 09:04

I notice that it finished up 15% in the US last night.

[wapper] 04/2/2021 08:47

Agree on chart: 42 / 60 / 80p + . Just been so many false dawns but when it does move it tends to be fast.Good luck

[georgethefourth] 04/2/2021 08:27

Chart looks very nice. I just bought more. Interestingly I could sell for 35 and also buy at 35

[wapper] 04/2/2021 08:25

Not sure why this is looking so strong today . Any ideas?

[kingston78] 15/1/2021 15:25

Does anyone have news update on this company? It was being traded quite actively last year and then activities died down. Today it has sprung up a bit. Thanks in advance.

[hodhasharon] 15/1/2021 15:21

Here she goes ladies.

[alexios1201] 08/1/2021 14:21

Microneedles technology is similar to this one posted by vive earlierhttps://www.researchgate.net/figure/Microneedle-patch-for-influenza-vaccination-A-The-microneedle-patch-contains-an-array_fig1_317979186

[alexios1201] 08/1/2021 14:21

Emergex Vaccines Provides an Update on Agreement with Midatech Pharma22nd November 2016/Oxford, UK, 22 November 2016 – Emergex Vaccines Holding Limited ("Emergex"), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.The exclusive licensing agreement covers the use of Midatech's proprietary gold nanoparticle platform in the development of vaccines for influenza, meningitis, bacterial pneumonia, Ebola virus, Marburg virus and viruses within the Arbovirus class, such as Zika and Dengue. This is the first deployment of Midatech's gold nanoparticles as a conventional vaccine for infectious diseases.Under the agreement, the licence, together with the Service and Manufacturing Agreement for both the synthesis and development manufacturing of cGMP material for clinical trials, was novated from Emergex Vaccines Limited to a related entity, Emergex Vaccines Holding Limited ("Emergex"), a private UK biotechnology company focused on developing synthetic T-cell vaccines against new and emerging infectious diseases.Midatech will continue to be entitled to receive certain milestone and royalty payments, as well as service fees, as part of the arrangement

[alexios1201] 08/1/2021 14:21

Microneedles technology for covid-19 vaccineEmergex have inclusivity to use Midatech Pharma microneedles tech

[alexios1201] 08/1/2021 14:20

Emergex Vaccines signs Collaboration Agreement with Brazil's Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine5th January 2021/Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of BrazilBio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world's most respected public health researchinstitutionsAbingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited ('Emergex', or 'the Company'), a company tackling major global infectious disease threats through the development of synthetic 'set point' vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine using Emergex's next generation synthetic T-Cell vaccine technology.The agreement provides a framework under which both parties will work together to progress certain immunotherapeutic programmes, including a vaccine candidate for COVID-19, through a regulatory pathway for the Brazilian National Health Service. Emergex will also support the performance of studies, including clinical trials, and to manufacture, market, promote and distribute certain infectious diseases vaccines within the National Health Service of Brazil.Emergex has already completed preclinical development work including toxicology and immunoproteomic research into the MHC Class I peptide expression library for cell surface expressed peptides on SARS-Cov-2 infected cells, which define the repertoire of an effective T-Cell immune response to the COVID-19 disease.In August 2020, a previous research collaboration between Emergex and Bio-Manguinhos / Fiocruz resulted in the determination of the MHC CD8 T-Cell epitope expression library for Fiocruz's commercial yellow fever vaccine.Bio-Manguinhos / Fiocruz and Emergex will share initial set up and development costs. Further financial details have not been disclosed

[aimmafia] 08/1/2021 13:31

Well I wasn't wrong here lol

[hodhasharon] 08/1/2021 12:03

another shot at 100p coming?

[aimmafia] 08/1/2021 12:01

What's the latest here? The chart looks like it could pop any moment?